Combining clinical and molecular heterogeneity within CASPR2-antibody mediated diseases: towards the underlying disease biology
- PMID: 32651250
- PMCID: PMC7509512
- DOI: 10.1136/jnnp-2020-323457
Combining clinical and molecular heterogeneity within CASPR2-antibody mediated diseases: towards the underlying disease biology
Keywords: autoimmune encephalitis; clinical neurology; immunology; neurogenetics; neuroimmunology.
Conflict of interest statement
Competing interests: SRI is a co-applicant and receives royalties on patent application WO/2010/046716 entitled ‘Neurological Autoimmune Disorders’. The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC-complex antibodies. SRI and SB are coinventors on ‘A Diagnostic Strategy to improve specificity of CASPR2 antibody detection.’ Ref. JA94536P.
Comment on
-
Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features.J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1076-1084. doi: 10.1136/jnnp-2020-323226. Epub 2020 Jul 10. J Neurol Neurosurg Psychiatry. 2020. PMID: 32651251
References
-
- Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010;133:2734–48. 10.1093/brain/awq213 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources